Physician profile
Pankaj Kumar
NPI 1073576922
$447.22
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.34 · 2020: $46.06 · 2021: $88.81 · 2022: $107 · 2023: $43.15 · 2024: $67.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95.43 | 2019-2022 | |
| Astellas Pharma US INC | $67.04 | 2024 | Xospata, Vyloy |
| Tosoh Bioscience, INC. | $48.00 | 2019 | |
| Eisai INC. | $41.58 | 2022-2023 | |
| Clovis Oncology, INC. | $32.20 | 2020 | |
| Pfizer INC. | $29.32 | 2020-2022 | |
| Adc Therapeutics America, INC. | $27.97 | 2021-2022 | |
| Seagen INC. | $23.99 | 2022 | |
| Cti Biopharma Corp. | $22.86 | 2023 | Vonjo |
| Genzyme Corporation | $22.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.74 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Sysmex Inostics INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.